tirzepatide surpass cvot A comparison of the effects of and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial SURPASS-CVOT shows tirzepatide delivers comparable

In adults with obesity or overweight and knee osteoarthritis, retatrutide at 12 mg produced 23.7% body weight loss (an average of 60 pounds) compared to 4.6% with placebo over a full treatment period

In addition to having effects on how your body metabolizes glucose and processes certain hormones, GLP-1 receptor agonists, as well as dual agonists like tirzepatide, act on receptors in your brain to curb cravings

By week 12, clinical trial data shows an average weight loss of 8.7% across all dose groups, with the 12mg group already approaching 10%

Obes Pillars 15:100186 Karakasis P, Patoulias D, Fragakis N, Mantzoros CS (2025) Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: systematic review and network meta-analysis

We take your concerns very seriously

It is the safety net that separates a medically supervised protocol from guesswork